Category Archives: Other

Viking Pops 31% on Maintenance Data; Roche Ph2 Enicepatide Results; New Lilly Manufacturing Facility; Obi Approved in the EU; Petrelintide Ph3 Program

A series of cardiometabolic-related news items has been observed from Viking Therapeutics, Roche, Lilly, NewAmsterdam Pharma, and Zealand Pharma. The news items seemingly come hot on the heels of Novo’s obesity-centric Capital Markets Day held Monday. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Positive Pants Part 2: Novo 2026 Capital Markets Day Highlights and Analysis

Part 2 of FENIX’s 2026 Novo CMD coverage recaps commentary on US commercial operations, global manufacturing & supply, and international operations. Each of these three components is viewed as integral to Novo’s future success while it attempts to maintain (and grow) its place in the CVRM market ahead of the onslaught of obesity competitors looking to eat its lunch.

This content is for Read Less members only.
Already a member? Log in here

Positive Pants Part 1: Novo 2026 Capital Markets Day Highlights and Analysis

Novo hosted its 2026 Capital Markets Day and provided updates on the strategic direction of the company across key commercial and R&D activities (view slides). While The Street and media sentiment seemed to be unduly negative on Novo’s direction (as evidenced by the -8% drop in the stock price), it appears the ongoing strong Wegovy pill launch and impending cagrisema launch should position the company to meet its operational targets in the next 3-5 years. However, the company may be challenged in the longer term, particularly as semaglutide approaches broader LOE. Below, FENIX provides details and insights from the event in Part 1 of 2. Part 2 will cover the importance of manufacturing and commercial execution with reflections from our May 2025 Obesity Spotlight on Novo Nordisk.

This content is for Read Less members only.
Already a member? Log in here

Novo Initiates Zenagamtide CVOT in Obesity; Novo Enters Purchase Agreement for Three Obesity Programs with Kallyope; Health Canada Approves Sandoz Generic Sema

Three cardiometabolic-related news items have been observed: Novo initiated a Ph3 study evaluating zenagamtide for ASCVD (view EUClinicalTrials record); Novo has entered into an asset purchase agreement with Kallyope to acquire three novel obesity drug programs (view LinkedIn post); and Sandoz received Health Canada approval for its generic semaglutide (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Obesity Spotlight Series: Emerging Players to Watch

In the thirteenth installment of FENIX’s Obesity Spotlight Series, FENIX has conducted a brief analysis of the emerging players in the obesity market. While previous editions of the spotlight series focused on the major players competing in the space, there is no shortage of smaller biotechs that could also shape the landscape in years to come. In this spotlight, FENIX highlights 10 smaller obesity players to watch (as well as honorable mentions), assessing their pipeline progress, competitive positioning, and potential attractiveness as future M&A targets.

This content is for Read Less members only.
Already a member? Log in here

Pfizer Initiates Ph3 Berobenatide OSA Study; Novo Ph3 Zenagamtide Study in Japan; Novo and Anthropic Partner for Drug and AI Development

Three cardiometabolic-related news items have been observed: Pfizer initiated the Ph3 QM berobenatide VESPER-OSA 1 study (view CT.gov record); Novo initiated the zenagamtide AMAZE 10 study in Japanese patients with obesity (view CT.gov record); and Novo and Anthropic entered into a collaboration to accelerate Novo’s drug development and AI-driven software development (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Ascendis/Novo Terminate QM Sema Agreement; Novo Cagrisema Switch Study; Dexcom Appoints COO; Arrowhead ARO-DIMER-PA Data; Elvinix/Zealand ZP3022 Licensing Agreement; Lilly Terminates Ph1 Obesity Asset; Medtronic Expands Separation from MiniMed; Tracky Launches 16-Day CGM in India

A series of cardiometabolic-related news items has been observed from Ascendis Pharma, Novo, Dexcom, Arrowhead Pharmaceuticals, Elvinix, Lilly, MiniMed, and Tracky. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Novo Rebranding; Corbus Topline Ph1b CB1 Data; New Foundayo DTC TV Ads; New Alveus Ph2 Obesity Study; Beta Bionics Patch Pump FDA Clearance; Senseonics Integrates with Beta Bionics’s iLet AID; September CHMP Agenda

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Corbus Pharmaceuticals, Lilly, Alveus Therapeutics, Beta Bionics, Senseonics, and EMA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Novo to Announce Org Changes; Novartis/Ionis Pelacarsen Updates

Two cardiometabolic-related news items have been observed: Novo Nordisk announced a Global Town Hall meeting for its employees ahead of its upcoming CMD (view X post), and Ionis provided additional updates on pelacarsen during the Wells Fargo Healthcare Conference 2026 (view webcast). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here